Imac holdings, inc. announces completion of third cohort of its phase 1 clinical study of umbilical cord-derived mesenchymal stem cells for the treatment of bradykinesia due to parkinson's disease

Brentwood, tenn., sept. 09, 2022 (globe newswire) -- imac holdings, inc. (nasdaq: back) (“imac” or “the company”), today announces it has completed the third cohort of its phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to parkinson's disease.
BACK Ratings Summary
BACK Quant Ranking